Meronem I.V. (Meropenem Anhydrous)

Meropenem works by binding to penicillin‑binding proteins on bacterial cell walls, inhibiting the final steps of peptidoglycan cross‑linking. This disruption weakens the cell wall, causing osmotic instability, cell lysis, and bacterial death. Its structure confers resistance to most β‑lactamases, giving it activity against a wide range of pathogens.

The prescribed dose of Meronem I.V. is determined by the treating physician based on the type and severity of infection, patient weight, renal function, and local susceptibility patterns. Dosing may be adjusted for renal impairment or in special populations, and the infusion rate is typically set to achieve therapeutic plasma concentrations.

Meropenem’s pregnancy category is listed as unknown, meaning safety data are limited. It should be used during pregnancy only if the potential benefit justifies any potential risk to the fetus. Likewise, while meropenem is excreted in breast milk, a decision to breastfeed while on therapy should consider the infant’s risk versus the mother’s therapeutic need.

To order Meronem I.V., submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details—including cold‑chain handling if needed—and assist with import documentation.

Meronem (meropenem) offers a broad spectrum similar to other carbapenems like imipenem‑cilastatin, but it has a slightly lower propensity for inducing seizures and is stable against many β‑lactamases. Compared with non‑carbapenem broad‑spectrum agents, meropenem provides superior coverage of resistant Gram‑negative organisms, including Pseudomonas aeruginosa, making it a preferred choice for multidrug‑resistant infections.

Meronem I.V. must be stored at 2‑8 °C (refrigerated) in its original container, protected from light. It should not be frozen or shaken. Before use, the solution may be inspected for particulate matter and discoloration. Once reconstituted, it should be used promptly according to the manufacturer’s stability guidelines.

Meronem I.V. is given by intravenous infusion. After reconstitution with the appropriate diluent, the solution is administered over 15‑30 minutes, depending on the dose and patient condition. Infusion rates may be adjusted for renal impairment or in patients at risk of seizures. Administration should follow aseptic technique and institutional protocols.

Serious adverse events include seizures, especially in patients with CNS disorders or renal dysfunction; severe allergic reactions such as anaphylaxis; Clostridioides difficile‑associated colitis; and significant renal or hepatic toxicity. Prompt recognition and discontinuation of therapy, along with appropriate supportive care, are essential if any of these events occur.

Meronem I.V. should be avoided in individuals with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Patients with uncontrolled seizure disorders, severe renal impairment without dose adjustment, or those who have experienced severe adverse reactions to similar agents should not receive this medication unless benefits clearly outweigh risks.